Key result
Uric acid-lowering therapies did not significantly improve left ventricular ejection fraction (MD 1.63%), 6-minute walk test, BNP levels, or mortality compared to placebo in heart failure patients.
Why the study?
Elevated serum uric acid is an independent predictor of adverse outcomes in cardiovascular disease, but the causal relationship between uric acid-lowering therapies and heart failure remains controversial.
Do uric acid-lowering therapies improve clinical and surrogate outcomes in patients with heart failure?
Population
Patients with heart failure across randomised controlled trials
Comparison
Uric acid-lowering therapies vs control
Design
Systematic review and meta-analysis of randomised controlled trials
Authors
Loading...
May reduce HF hospitalizations in HFpEF without mortality benefit; leaves open need for confirmatory RCTs.
Meta-Analysis (n=864)
Do uric acid-lowering therapies improve clinical and surrogate outcomes in patients with heart failure?
Mean Difference: 1.63 (95% CI -1.61–4.88)
p-value: p=0.32
Uric acid-lowering therapies do not improve cardiac function, exercise capacity, or mortality in patients with heart failure, suggesting uric acid may be a risk marker rather than a causal factor.
Xu et al. (2021) conducted a meta-analysis in Heart failure (n=864). Uric acid-lowering therapies vs. Placebo was evaluated on Left ventricular ejection fraction (LVEF) (MD 1.63%, 95% CI -1.61 to 4.88, p=0.32). Uric acid-lowering therapies did not significantly improve left ventricular ejection fraction (MD 1.63%), 6-minute walk test, BNP levels, or mortality compared to placebo in heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: